DocMorris AG Shareholders Approve Capital Increase

On May 8, 2025, at the Annual General Meeting in Frauenfeld, DocMorris AG shareholders approved all proposals from the Board of Directors, including a pivotal capital increase. This decision allows DocMorris to raise approximately CHF 200 million through a rights issue to bolster growth in their prescription medicines segment and potentially repay a CHF 95 million convertible bond due in 2026. The process will see existing shareholders receiving subscription rights for new shares, with trading opening on May 13, 2025, on the SIX Swiss Exchange.

The underwriting of these rights is ensured by a banking syndicate. The new shares are priced at CHF 5.75 each, with the initial trading day scheduled for May 22, 2025. Any unsubscribed shares are planned to transition to a public offering within Switzerland and private placements internationally. DocMorris emphasizes that any security offers will adhere strictly to the prospectus published post-AGM.